Central nervous system metastases in patients with high‐risk breast carcinoma after multimodality treatment
Open Access
- 27 August 2004
- Vol. 101 (8) , 1760-1766
- https://doi.org/10.1002/cncr.20530
Abstract
BACKGROUND: The current study was performed to determine the incidence of central nervous system (CNS) metastases and to examine associated disease characteristics in a group of patients with locally advanced breast carcinoma (LABC) or inflammatory breast carcinoma (IBC) treated at The University of Texas M. D. Anderson Cancer Center (Houston, TX).METHODS: Seven hundred sixty‐eight patients treated with multimodality therapy between 1982 and 2000 in any of 6 neoadjuvant trials were eligible for the current study. Five hundred ninety‐two patients (77%) had LABC, and 176 (23%) had IBC. CNS disease was defined as the presence of brain metastases or leptomeningeal disease. Time to detection of CNS disease and overall survival were estimated using the Kaplan–Meier product‐limit method, and differences were evaluated using log‐rank tests.RESULTS: The median patient age was 48 years. Most tumors were classified as T4 lesions (58%) and exhibited lymph node involvement (78%). Fifty‐one percent of all tumors had positive hormone receptor status. At a median follow‐up duration of 9.5 years, 61 patients (8%) had developed CNS metastases, with the CNS representing the first site of recurrence for 38 of these 61 (63%). Characteristics associated with the development of CNS metastases over time included negative hormone receptor status (P = 0.03), Grade 3 disease (P = 0.01), and larger tumor size (P = 0.02). The median time to detection of CNS metastases was 2.3 years. Ten patients (16%) remained alive after treatment for CNS metastases. The median survival from the time of diagnosis of CNS metastases was 8 months.CONCLUSIONS: CNS metastases from breast carcinoma were relatively uncommon and were strongly associated with more aggressive clinical presentation. Survival from the time of diagnosis of such metastases generally was short. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 22 references indexed in Scilit:
- Is breast cancer survival improving?Cancer, 2003
- Diagnosis and Management of Central Nervous System Metastases from Breast CancerThe Oncologist, 2003
- Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.Journal of Neuro-Oncology, 2002
- Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgeryAnnals of Neurology, 1993
- Brain metastases in breast cancer; natural history, prognostic factors and outcomeJournal of Neuro-Oncology, 1993
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990
- The effect of prior adjuvant chemotherapy on survival in metastatic breast cancerJournal of Surgical Oncology, 1988
- Breast carcinomaAmerican Journal of Clinical Oncology, 1984
- The World Health Organization Histological Typing of Breast Tumors—Second EditionAmerican Journal of Clinical Pathology, 1982
- Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancerPublished by Elsevier ,1981